-
公开(公告)号:US11464785B2
公开(公告)日:2022-10-11
申请号:US16191119
申请日:2018-11-14
申请人: Omeros Corporation
IPC分类号: A61K31/4162 , A61K31/4439 , A61K31/505 , A61K31/44 , A61K31/4015 , A61K31/381 , A61K31/551 , A61K31/5513 , A61K31/135 , A61K31/4025 , A61K31/4178 , A61K31/519 , A61K31/4985 , A61K31/35 , A61K31/433 , A61K31/435 , A61K31/46 , A61K31/527 , A61K31/496 , A61K31/53 , A61K31/5377 , A61K31/465 , A61K31/55 , A61K31/517 , A61K31/485 , A61K31/454 , A61K31/385 , A61K31/357 , A61K31/337 , A61K31/197 , A61K31/137 , A61K45/06
摘要: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
-
公开(公告)号:US11453709B2
公开(公告)日:2022-09-27
申请号:US16930973
申请日:2020-07-16
申请人: Omeros Corporation
摘要: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.
-
公开(公告)号:US20220175726A1
公开(公告)日:2022-06-09
申请号:US17552872
申请日:2021-12-16
申请人: Omeros Corporation
IPC分类号: A61K31/407 , A61K9/00 , A61K31/138 , A61K31/137
摘要: The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.
-
公开(公告)号:US20220064330A1
公开(公告)日:2022-03-03
申请号:US17103672
申请日:2020-11-24
申请人: Omeros Corporation
摘要: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from, or at risk for developing HSCT-IPS and/or suffering from, or at risk for developing HSCT-CLS and/or suffering from, or at risk for developing HSCT-FO and/or suffering from, or at risk for developing HSCT-ES. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
公开(公告)号:US11207275B2
公开(公告)日:2021-12-28
申请号:US15871768
申请日:2018-01-15
申请人: Omeros Corporation
IPC分类号: A61K31/00 , A61K31/135 , A61K31/137 , A61K31/197 , A61K31/381 , A61K31/454 , A61K31/485 , A61K31/4985 , A61K31/517 , A61K31/519 , A61K31/337 , A61K31/357 , A61K31/385 , A61K31/4015 , A61K31/4025 , A61K31/4178 , A61K31/44 , A61K31/505 , A61K31/55
摘要: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
-
公开(公告)号:US20210290605A1
公开(公告)日:2021-09-23
申请号:US17223836
申请日:2021-04-06
申请人: Omeros Corporation
IPC分类号: A61K31/4422 , A61K9/00 , A61K9/08 , A61K31/00 , A61K31/192 , A61K31/21 , A61K31/40 , A61K31/44 , A61K31/455 , A61L31/16
摘要: Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents and a buffering agent.
-
公开(公告)号:US20210171512A1
公开(公告)日:2021-06-10
申请号:US17112887
申请日:2020-12-04
申请人: Omeros Corporation
发明人: Neil S. CUTSHALL , Jennifer Lynn GAGE , Sara Rebecca GOLDSTEIN , Santosh Kumar KESHIPEDDY , Do Yeon KWON , Robert Huerta LEMUS , Thomas L. LITTLE , Markus METZ , Peter Kurt NOLLERT VON SPECHT , Loren Michael PRICE , Jennifer TSOUNG
IPC分类号: C07D413/12 , C07D211/60 , C07F9/6561 , C07D401/14 , C07D401/06 , C07D409/12
摘要: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
-
8.
公开(公告)号:US20200317510A1
公开(公告)日:2020-10-08
申请号:US16909578
申请日:2020-06-23
申请人: Omeros Corporation
发明人: W. Jason Cummings , Gregory A. Demopulos , Thomas Dudler , Larry W. Tjoelker , Christi L. Wood , Munehisa Yabuki
IPC分类号: B82Y25/00 , C09K11/77 , C01F17/206 , H01F1/00
摘要: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
-
公开(公告)号:US20200270125A1
公开(公告)日:2020-08-27
申请号:US16837600
申请日:2020-04-01
申请人: Omeros Corporation
发明人: W. Jason Cummings , Gregory A. Demopulos , Thomas Dudler , Larry W. Tjoelker , Christi L. Wood , Munehisa Yabuki
IPC分类号: B82Y25/00 , C09K11/77 , C01F17/206 , H01F1/00
摘要: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
-
公开(公告)号:US10745274B1
公开(公告)日:2020-08-18
申请号:US16837600
申请日:2020-04-01
申请人: Omeros Corporation
发明人: W. Jason Cummings , Gregory A. Demopulos , Thomas Dudler , Larry W. Tjoelker , Christi L. Wood , Munehisa Yabuki
IPC分类号: C12N9/64 , B82Y25/00 , C09K11/77 , H01F1/00 , C01F17/206
摘要: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
-
-
-
-
-
-
-
-
-